Oculis has completed enrollment in the first stage of a phase 3 study evaluating a topical eye drop for the treatment of diabetic macular edema, according to a press release.
The DIAMOND study will assess the efficacy and safety of OCS-01, a high-concentration topical formulation of dexamethasone that could be the first noninvasive treatment for DME, the release said.
The study’s primary endpoint is the mean change in best corrected visual acuity ETDRS letter score from baseline to week 6 (stage 1) and to week 52 (stage 2). The estimated (Read more...)